The board of directors of the The United Laboratories International Holdings Limited announced that on 29 August 2023, the application for the clinical trial of class 1 innovative new drug UBT251 Injection self-developed by The United Bio-Technology (Hengqin) Co. Ltd., a wholly-owned subsidiary of the Company, on indication of adult type 2 diabetes was approved by China National Medical Products Administration, with reference number of CXHL2300655. The product has also applied for indications of weight management and non-alcoholic fatty liver, and is currently in the final review stage.

At present, the Company is the first enterprise in China and the second enterprise in the world to be approved for the clinical trials of a long-acting triple agonist of GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide)/GCG (glucagon) prepared by chemical synthetic polypeptide. In the future, the Company will continue to commit itself to the research and development of new products, and focus on enhancing its competitiveness and creativity in the biopharmaceutical industry, with a view of creating more benefits for the Company and its shareholders.